Will Novavax Be Worth as Much as Moderna by 2025?

Novavax (NASDAQ: NVAX) has given investors a bumpy ride this year. It slid 42% from a high, after falling behind on regulatory submissions for its coronavirus vaccine candidate. But the biotech stock may be on its way up. The company recently completed regulatory submissions to several countries and the European Union. A submission in the U.S. should happen before the end of the year.

And Novavax has even scored two authorizations -- in Indonesia and the Philippines -- so sales may start rolling in soon. The company also is working on a way to make itself a top player in a post-pandemic world.

With all of this good news for both the near term and the long term, it's time to think about Novavax's growth potential. Could this vaccine company climb enough in value to be worth as much as bigger rival Moderna (NASDAQ: MRNA)? Let's find out.

Source Fool.com